Pre-made Brolucizumab benchmark antibody ( scFv, anti-VEGFA therapeutic antibody, Anti-VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brolucizumab, sold under the trade name Beovu, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-083-1mg	1mg	3090
GMP-Bios-ab-083-10mg	10mg	Inquiry
GMP-Bios-ab-083-100mg	100mg	Inquiry
GMP-Bios-ab-083-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Brolucizumab biosimilar, scFv, Anti-VEGFA Antibody: Anti-VPF/VEGF/MVCD1 therapeutic antibody
INN Name	Brolucizumab
Target	VEGFA
Format	scFv
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	na
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2014
Year Recommended	2015
Companies	ESBATech;Alcon
Conditions Approved	Wet age-related macular degeneration
Conditions Active	Diabetic macular oedema;Retinal vein occlusion;Diabetic retinopathy
Conditions Discontinued	na
Development Tech	na